Stephens & Co. analyst Mason Carrico has reiterated an Equal-Weight rating on Myriad Genetics (MYGN) but significantly reduced its price target from $5 to $3. This downward revision in the price target suggests a more cautious outlook on the company's near-term valuation, potentially impacting investor sentiment.
Stephens & Co. analyst Mason Carrico maintained an 'Equal-Weight' rating on Myriad Genetics but lowered the price target from $5 to $3. This action indicates that while the analyst believes the stock will perform in line with the broader market, the perceived fair value has decreased significantly. This could lead to negative short-term pressure on MYGN's stock price as investors react to the reduced valuation. For traders, this presents a potential short-term selling opportunity or a signal to re-evaluate existing long positions, as the lowered price target suggests a more challenging outlook for the company's growth or profitability in the near future.